Excitotoxicity in the pathogenesis of neurological and psychiatric disorders:

Olloquequi	J.

Cornejo-Córdova E.

Therapeutic implications

Verdaguer E.

Soriano F.X.

Binvignat O.

Auladell C.

Camins A.

Neurological and psychiatric disorders are leading contributors to the global disease burden, having a serious impact on the quality of life of both patients and their relatives. Although the molecular events underlying these heterogeneous diseases remain poorly understood, some studies have raised the idea of common mechanisms involved. In excitotoxicity, there is an excessive activation of glutamate receptors by excitatory amino acids, leading to neuronal damage. Thus, the excessive release of glutamate can lead to a dysregulation of Ca2+ homeostasis, triggering the production of free radicals and oxidative stress, mitochondrial dysfunction and eventually cell death. Although there is a consensus in considering excitotoxicity as a hallmark in most neurodegenerative diseases, increasing evidence points to the relevant role of this pathological mechanism in other illnesses affecting the central nervous system. Consequently, antagonists of glutamate receptors are used in current treatments or in clinical trials in both neurological and psychiatric disorders. However, drugs modulating other aspects of the excitotoxic mechanism could be more beneficial. This review discusses how excitotoxicity is involved in the pathogenesis of different neurological and psychiatric disorders and the promising strategies targeting the excitotoxic insult. © 2018, © The Author(s) 2018.

Alzheimer?s disease

autism spectrum disorder

depression
Glutamate
stroke
acetylcysteine
calcium ion
cycloserine
fludrocortisone
free radical
glutamate receptor
glutamic acid
ketamine
memantine
n methyl dextro aspartic acid receptor blocking agent
neu 2000kwl
neu 2000kwl riluzole
riluzole
riluzole tissue plasminogen activator
riluzole tissue plasminogen activator unclassified drug
riluzole tissue plasminogen activator unclassified drug ursodeoxycholic acid
riluzole tissue plasminogen activator unclassified drug ursodeoxycholic acid glutamate receptor
riluzole tissue plasminogen activator unclassified drug ursodeoxycholic acid glutamate receptor glutamic acid
riluzole tissue plasminogen activator unclassified drug ursodeoxycholic acid glutamate receptor glutamic acid Alzheimer disease
riluzole tissue plasminogen activator unclassified drug ursodeoxycholic acid glutamate receptor glutamic acid Alzheimer disease amyotrophic lateral sclerosis
riluzole tissue plasminogen activator unclassified drug ursodeoxycholic acid glutamate receptor glutamic acid Alzheimer disease amyotrophic lateral sclerosis autism

disorders of mitochondrial functions
drug targeting
excitotoxicity
human
mental disease
neurologic disease
nonhuman
oxidative stress
Parkinson disease
pathogenesis
priority journal
Review
schizophrenia
signal transduction
animal
mental disease
metabolism
nerve cell
neurologic disease
pathology
Animals
Glutamic Acid
Humans
Mental Disorders
Nervous System Diseases

Neurons

Receptors, Glutamate